Featured Research

from universities, journals, and other organizations

New compound targets key mechanism behind lymphoma

Date:
April 3, 2012
Source:
Fox Chase Cancer Center
Summary:
Scientists have come one step closer to developing the first treatment to target a key pathway in lymphoma.

Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on April 3.

Related Articles


"It's an exciting time to be involved in lymphoma treatment and research," says study author Mitchell Smith, MD, PhD, director of Lymphoma Service at Fox Chase. "There's a new understanding of the disease, and new drugs to treat it. I am optimistic that over the next couple of years treatments will continue to get even better and less toxic."

During the study, Smith and his colleagues investigated a compound known as TL32711 (Birinapant), developed by TetraLogic Pharmaceuticals in Malvern, Pennsylvania. The compound works by blocking the process cells used to avoid death, he explains -- in other words, it inhibits the process that inhibits cell death. "TL32711 is like a double-negative. It inhibits the inhibitor, and therefore makes cells more sensitive to dying."

To test whether TL32711 works better in some types of lymphomas than others, Smith and his team added it to various lymphoma cells. Since compounds tend to work best when given in combination with other drugs, in some cells they added another compound known as TRAIL, which targets tumor cells.

The researchers found that some types of lymphoma appeared more vulnerable to the effects of TL32711, suggesting these patients should be the first to try the finished product in clinical trials. Specifically, they saw that follicular lymphoma cells and some types of diffuse large B cell lymphomas were more likely to die following treatment. Not surprisingly, adding TRAIL to the mix appeared to make TL32711 even more effective at killing lymphoma cells. "We saw the combination worked better than either one alone," says Smith.

Importantly, the researchers saw the cells didn't just die -- they died because of the action of the compounds, explains Smith. TL32711 works by enhancing cell death -- known formally as apoptosis -- and just before cells experience apoptosis, they activate proteins known as caspases. Sure enough, after exposure to the compounds, the level of active caspases increased, confirming the cells were undergoing more apoptosis. "This result confirms that the cells are dying the way they should when you add these compounds," says Smith.

TL32711 is not yet available in the clinic, says Smith, but already some clinical trials are enrolling patients to test its effects. He and his colleagues plan to continue to test the compound in animals, to get a better sense of how it should best be used in humans.

"We're getting a much better understanding of why lymphoma cells don't die," he adds. "We're starting to see drugs that hit different pathways in the cell. Our research is about trying to take the compounds that target this particular pathway forward in the most efficient way possible."

Dr. Smith's co-authors include Indira Joshi at Fox Chase Cancer Center, along with colleagues from TetraLogic Pharmaceuticals.

This work was supported in part by funding from TetraLogic Pharmaceuticals.


Story Source:

The above story is based on materials provided by Fox Chase Cancer Center. Note: Materials may be edited for content and length.


Cite This Page:

Fox Chase Cancer Center. "New compound targets key mechanism behind lymphoma." ScienceDaily. ScienceDaily, 3 April 2012. <www.sciencedaily.com/releases/2012/04/120403111722.htm>.
Fox Chase Cancer Center. (2012, April 3). New compound targets key mechanism behind lymphoma. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2012/04/120403111722.htm
Fox Chase Cancer Center. "New compound targets key mechanism behind lymphoma." ScienceDaily. www.sciencedaily.com/releases/2012/04/120403111722.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Reuters - Innovations Video Online (Dec. 21, 2014) A team of scientists led by Danish chemist Jorn Christensen says they have isolated two chemical compounds within an existing antipsychotic medication that could be used to help a range of failing antibiotics work against killer bacterial infections, such as Tuberculosis. Jim Drury went to meet him. Video provided by Reuters
Powered by NewsLook.com
Hugging It Out Could Help You Ward Off A Cold

Hugging It Out Could Help You Ward Off A Cold

Newsy (Dec. 21, 2014) Carnegie Mellon researchers found frequent hugs can help people avoid stress-related illnesses. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins